Skip to Main Content

Sarah Weiss, MD

Assistant Professor Adjunct
DownloadHi-Res Photo

Additional Titles

Assistant Professor (Medical Oncology)

About

Titles

Assistant Professor Adjunct

Assistant Professor (Medical Oncology)

Biography

Sarah A. Weiss, MD, Assistant Professor of Medicine at Yale School of Medicine completed her internship and residency at the Montefiore Medical Center of the Albert Einstein College of Medicine in Bronx, NY and received her medical degree from the Albert Einstein College of Medicine of Yeshiva University. She completed a 3-year fellowship in Hematology and Medical Oncology at New York University School of Medicine and a 1-year post-doctoral fellowship with a focus on tissue-based prognostic markers in melanoma.

Dr. Weiss is a member of both the American Society of Clinical Oncology and the Society for Immunotherapy of Cancer. Some of her ongoing research includes study of new immunotherapeutic strategies for patients with melanoma whose disease has progressed on standard therapy.

Appointments

Other Departments & Organizations

Education & Training

Post-Docotoral Research Fellowship (Melanoma)
New York University (2016)
Fellowship
New York University (2015)
Residency
Montefiore Medical Center of the Albert Einstein College of Medicine (2012)
MD
Albert Einstein College of Medicine (2009)

Research

Overview

Dr. Weiss joined the Melanoma and Renal Cell Carcinoma Disease Aligned Research Team at Yale in August 2016 and has a growing clinical practice. Her primary research interests are to develop innovative clinical trials for the management of advanced melanoma, and to identify and integrate prognostic and predictive biomarkers into clinical practice. She is currently the site Principal Investigator on several clinical trials including a study of Apexigen’s CD40 agonist in combination with nivolumab in patients with melanoma who are resistant to PD-1 immune checkpoint inhibitors. This has led to an investigator-initiated clinical trial protocol that Dr. Weiss wrote based off of preclinical work conducted in the Kaech and Bosenberg laboratories here at Yale, aimed at overcoming resistance to PD-1/PD-L1 agents by targeting both the innate and adaptive immune systems with a triple combination of a CD40 agonist, CSF1R inhibitor, and PD-1 inhibitor.

Medical Subject Headings (MeSH)

Immunotherapy; Melanoma

Research at a Glance

Yale Co-Authors

Frequent collaborators of Sarah Weiss's published research.

Publications

2024

2023

Get In Touch

Contacts

Appointment Number
Clinic Fax Number